From hospital to home: How carvedilol helps reduce mortality in heart failure with reduced ejection fraction

Heart failure with reduced ejection fraction (HFrEF) remains a major cause of morbidity and mortality, with recurrent hospitalizations often marking a challenging phase in the patient journey. For patients, being discharged is not the end of their treatment journey. While discharge from the hospital represents an important milestone, long-term management is essential to reduce the risk of clinical deterioration and improve survival.¹

One of the medicines that has played an important role in improving outcomes for patients with HFrEF is carvedilol, a beta-blocker recommended as part of guideline-directed treatment for heart failure. Guideline-directed medical therapy (GDMT) refers to the combination of evidence-based medicine recommended to improve outcomes for patients with HFrEF. Current treatment generally centers on four key pillars: an angiotensin receptor–neprilysin inhibitor (ARNi), a mineralocorticoid receptor antagonist (MRA), and a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and a beta-blocker such as carvedilol. Together, these therapies work through different pathways to help reduce symptoms, slow disease progression, lower the risk of hospitalization, and improve survival.

As one of the recommended evidence-based beta-blockers, carvedilol is an important part of this four-pillar approach to long-term HFrEF management. By helping slow the heart rate and reduce the effects of excessive stress on the heart, carvedilol can help the heart work more efficiently over time.² 

Carvedilol reduces the risk of death and hospitalization in severe HFrEF

Heart failure treatment is not only about relieving symptoms. The goal is also to help prevent the condition from getting worse and reduce the chances of another hospital stay.

The benefits of carvedilol were demonstrated in the landmark COPERNICUS study, which looked at patients with severe chronic heart failure. The COPERNICUS (Carvedilol Prospective Randomized Cumulative Survival) trial was a randomized, double-blind, placebo-controlled study involving 2,289 patients with severe chronic heart failure, symptoms at rest or with minimal exertion, and a left ventricular ejection fraction (LVEF) <25%. Patients were randomized to carvedilol (n=1,156) or placebo (n=1,133) and followed for an average of 10.4 months. Carvedilol reduced the risk of death by 35% compared with placebo (HR 0.65; 95% CI, 0.52–0.81; P=0.00013). It also reduced the combined risk of death or cardiovascular hospitalization by 27% (P=0.00002) and death or heart failure hospitalization by 31% (P=0.000004). Patients receiving carvedilol spent 27% fewer days in the hospital for any reason (P=0.0005) and 40% fewer days hospitalized for heart failure (P<0.0001). After 6 months, more patients receiving carvedilol reported improvement and fewer reported worsening of their condition (P=0.0009). Serious adverse events were also less frequent with carvedilol (P=0.002), supporting its role in improving both survival and clinical outcomes in patients with severe heart failure.³

These findings highlight an important principle in HFrEF care: effective treatment should not end when symptoms improve or the patient leaves the hospital. Continued evidence-based therapy can help address the underlying neurohormonal mechanisms that contribute to disease progression and support sustained clinical stability especially in patients with severe chronic heart failure.³

Continued guideline-directed therapy helps sustain care beyond discharge

The transition from hospital to home is therefore an important opportunity to reinforce long-term heart failure management. Appropriate initiation and continuation of guideline-directed therapies, alongside monitoring for tolerability and clinical response, can help patients remain on treatment and reduce the risk of subsequent events.^4,5

For eligible patients with HFrEF, carvedilol remains an established component of guideline-directed therapy, with robust clinical evidence supporting its role in improving survival and reducing heart failure-related morbidity.³ In terms of dosing, for patients with HFrEF, carvedilol is typically started at a low dose of 3.125 mg twice daily and gradually increased as tolerated. The dose may be stepped up to 6.25 mg twice daily, 12.5 mg twice daily, and ultimately 25 mg twice daily, with each increase generally made at intervals of at least 2 weeks. This gradual approach allows clinicians to assess the patient's blood pressure, heart rate, symptoms, and overall tolerance before increasing the dose. If a higher dose is not well tolerated, a lower dose may be maintained. The goal of guideline-directed medical therapy is to reach the target dose of 25 mg twice daily, as tolerated, helping patients receive the evidence-based benefits of carvedilol while supporting safe, long-term treatment.²

Carvedilol (Carvida®) provides an evidence-based beta-blocker option for appropriate patients with HFrEF, supporting the goal of moving beyond hospital discharge toward sustained, long-term heart failure management.

Abbreviations: ARNi: angiotensin receptor–neprilysin inhibitor; GDMT: guideline-directed medical therapy; HFrEF: heart failure with reduced ejection fraction; left ventricular ejection fraction: LVEF; MRA: mineralocorticoid receptor antagonist; SGLT2i: sodium-glucose cotransporter-2 inhibitor.


^{References: 1. Shahim B, et al. Card Fail Rev 2023;9:e11. 2. Singh S, Preuss CV. StatPearls. 2026 Jan. 3. Packer M, et al. Circulation 2002;106:2194-2199. 4. MacGregor JF, et al. Congest Heart Fail 2009;15:5-8. 5. Neglia D, et al. Heart 2007;93:808-813.}